Notice of Intent - Illumina MiSeq i100 series instruments

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

NATIONAL INSTITUTES OF HEALTH - CC

Contract Value

Not provided

Codes & Classification
Solicitation Number

NOI-OLAO-CC-27-000836

NAICS

334516 - Analytical Laboratory Instrument Manufacturing

Classification Code

6640

Additional Details
Set Aside

NONE

Place of Performance

Bethesda, Maryland, UNITED STATES

SourceSAM
The National Institutes of Health, Clinical Center (NIH-CC), has issued a presolicitation Notice of Intent (NOI-OLAO-CC-27-000836) regarding the planned acquisition of two Illumina MiSeq i100 series instruments. This procurement is intended to support the NIH HLA Laboratory in Bethesda, Maryland, by ensuring the continued capability to produce high-resolution HLA typing results, which are critical for the numerous transplant protocols managed by the laboratory. The primary objective of this acquisition is to replace the laboratory’s existing Illumina MiSeq instruments, which were purchased in 2019 and 2022. The current models are approaching the end of their service life, as the vendor, Illumina, Inc., has announced the discontinuation of service for these instruments. The timely procurement of the new MiSeq i100 series units is essential to allow for validation and seamless transition before the existing instruments are no longer supported, thereby maintaining the laboratory’s ability to deliver the highest quality HLA typing necessary for successful transplant outcomes. The Illumina MiSeq i100 series is an integrated platform capable of clonal amplification, genomic DNA sequencing, and comprehensive data analysis—including base calling, alignment, variant calling, and reporting—in a single run. This high level of integration and performance is required to meet the stringent quality and resolution demands of the NIH HLA Laboratory’s transplant protocols. The laboratory’s established procedures and quality control measures are already tailored to the MiSeq platform, further underscoring the necessity for direct replacement with compatible instruments. This procurement is being conducted under the statutory authority of 41 U.S.C. 253(c)(1), as implemented by FAR 6.302-1, which allows for other than full and open competition when only one responsible source can satisfy agency requirements. As such, NIH-CC intends to negotiate exclusively with Illumina, Inc. However, the government will consider capability statements from other responsible sources that can provide the required instruments. Interested parties must submit their statements by 12:00 PM EST on November 27, 2026, referencing NOI-OLAO-CC-27-000836, to the primary contact, Valerie Gregorio, at [email protected]. The procurement is classified under NAICS code 334516 (Analytical Laboratory Instrument Manufacturing) and Product Service Code 6640. There are no set-aside requirements for this opportunity. The place of performance is Bethesda, Maryland, United States. This notice is not a request for proposal, and the government reserves the right to make a determination not to compete this requirement based on the responses received. Contractors interested in this opportunity should carefully consider their ability to meet the highly specialized requirements and compatibility needs outlined in the notice. For further details, the official notice can be accessed at: https://sam.gov/opp/8eb0ea7110504ca7bcc6eb99ffeb6296/view.